Skip to main content

Table 1 Pharmacology properties and therapeutic benefits of MAOB inhibitors in clinical use for Parkinson's disease

From: Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

  Selegiline Rasagiline
Recommended dosage 10 mg daily 1 mg daily
Bioavailability Unknown [61] 36% [62]
Half-life 10 hours [61] 0.6 – 2 hours [62]
Metabolite L-amphetamine like metabolites [61] Aminoindan [62]
Symptomatic monotherapy Efficacious [15] Efficacious [30, 35]
Adjunct to levodopa and treatment to motor complications Likely efficacious [15] Efficacious [28, 29]
- Levodopa sparing effect - Levodopa sparing effect
- Reduction in motor fluctuation - Reduction in motor fluctuation
Disease-modification Insufficient evidence Insufficient evidence